PNT — POINT Biopharma Global Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $1.33bn
- $998.03m
- $226.58m
Brief: POINT Biopharma - As Of June 30, 2022, Had About $204.3 Mln In Cash, Cash Equivalents & Investments
Brief: POINT Biopharma Global Reports Qtrly Results Ended June 30
Point Biopharma Global Inc Expected To Post A Loss Of 22 Cents A Share: Earnings Preview
Brief: Point Biopharma Global Inc Files For Mixed Shelf Of Up To $400 Million
Brief: Point Biopharma Unveils Frontier A Pan-Cancer Fap-Α Targeted Clinical Program
Point Biopharma Global Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: POINT Biopharma Posts Qtrly Loss Per Share $0.18
Brief: POINT Biopharma Global Says Entered Fourth Amendment To Certain Exclusive Sublicense Agreement
Point Biopharma Global Inc Expected To Post A Loss Of 21 Cents A Share: Earnings Preview
Brief: POINT Biopharma Confirms No Supply Shortages Of 177177LU-PNT002 For The Splash Trial
Brief: First European Union Patient Dosed with 177Lu-PNT2002 In Phase 3 SPLASH Trial
Brief: Point Biopharma To Present On Its its Pan-Cancer FAP-Alpha Targeted Program At AACR Annual Meeting
Point Biopharma Global Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: Point Biopharma Global Posts Quarterly Loss Per Share Of 16 Cents
FDA nod for Novartis's radiotherapy to bode well for other biotechs - Guggenheim
Point Biopharma Global Inc Expected To Post A Loss Of 23 Cents A Share: Earnings Preview
Brief: Point Biopharma Confirms No Delays To Splash Trial Due To Recent Global Lutetium Supply Interruption
Brief: Point Biopharma Announces Publication Of Findings From Of Splash Trial In MCRPC
Brief: Point Biopharma Provides Early-Stage Program Updates